[{"orgOrder":0,"company":"Aeolian Biotech","sponsor":"","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"Multivalent Pneumococcal conjugate vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aeolian Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aeolian Biotech \/ ","highestDevelopmentStatusID":"4","companyTruncated":"Aeolian Biotech \/ "}]

Find Clinical Drug Pipeline Developments & Deals for Multivalent Pneumococcal conjugate vaccine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aeolian Biotech

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Aeolian Biotech

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under an exclusive licensing agreement, Aeolian has been granted a license that includes compositions and methods of use of pneumococcal vaccines in the U.S. and Japan, and pending in other geographies.

                          Brand Name : iPCV22

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 30, 2023

                          Lead Product(s) : Multivalent Pneumococcal conjugate vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor :

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank